StockData
ENDRA Life Sciences Inc. logo

ENDRA Life Sciences Inc. (NDRA) stock

NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$4.04+0.12 (+2.93%)

Close on Nov 18, 2026Market cap $6.05MP/E –Yield –

ENDRA Life Sciences r&d expenses

Research and development expenses are spending on new products and technology.

ENDRA Life Sciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.95M, down 16.7% year over year. For fiscal 2025 it was $1.85M, down 42.0% from the year before. The highest annual figure on record is $6.57M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.85M-42.0%
FY2024Dec 31, 2024$3.19M-36.2%
FY2023Dec 31, 2023$5.00M-23.7%
FY2022Dec 31, 2022$6.55M+19.5%
FY2021Dec 31, 2021$5.48M-7.4%
FY2020Dec 31, 2020$5.92M-10.0%
FY2019Dec 31, 2019$6.57M+39.2%
FY2018Dec 31, 2018$4.72M+144.6%
FY2017Dec 31, 2017$1.93M+289.8%
FY2016Dec 31, 2016$495.38K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$233.67K-38.7%
Q1 FY2026Mar 31, 2026$776.41K+46.9%
Q4 FY2025Dec 31, 2025$508.14K-20.3%
Q3 FY2025Sep 30, 2025$432.11K-45.6%
Q2 FY2025Jun 30, 2025$381.06K-46.8%
Q1 FY2025Mar 31, 2025$528.69K-49.2%
Q4 FY2024Dec 31, 2024$637.96K+10.1%
Q3 FY2024Sep 30, 2024$794.44K-51.3%
Q2 FY2024Jun 30, 2024$716.37K-48.8%
Q1 FY2024Mar 31, 2024$1.04M-25.1%
Q4 FY2023Dec 31, 2023$579.35K-65.2%
Q3 FY2023Sep 30, 2023$1.63M-10.8%
Q2 FY2023Jun 30, 2023$1.40M-24.2%
Q1 FY2023Mar 31, 2023$1.39M+14.7%
Q4 FY2022Dec 31, 2022$1.66M+16.9%
Q3 FY2022Sep 30, 2022$1.83M+56.0%
Q2 FY2022Jun 30, 2022$1.85M+5.9%
Q1 FY2022Mar 31, 2022$1.21M+6.3%
Q4 FY2021Dec 31, 2021$1.42M+24.4%
Q3 FY2021Sep 30, 2021$1.17M-33.7%
Q2 FY2021Jun 30, 2021$1.74M+17.3%
Q1 FY2021Mar 31, 2021$1.14M-24.8%
Q4 FY2020Dec 31, 2020$1.14M-43.6%
Q3 FY2020Sep 30, 2020$1.77M+20.5%
Q2 FY2020Jun 30, 2020$1.49M+14.0%
Q1 FY2020Mar 31, 2020$1.52M-14.4%
Q4 FY2019Dec 31, 2019$2.03M+93.0%
Q3 FY2019Sep 30, 2019$1.47M+26.3%
Q2 FY2019Jun 30, 2019$1.30M+55.4%
Q1 FY2019Mar 31, 2019$1.77M+6.3%
Q4 FY2018Dec 31, 2018$1.05M-22.7%
Q3 FY2018Sep 30, 2018$1.16M+287.0%
Q2 FY2018Jun 30, 2018$839.76K+380.6%
Q1 FY2018Mar 31, 2018$1.67M+1641.7%
Q4 FY2017Dec 31, 2017$1.36M+755.6%
Q3 FY2017Sep 30, 2017$300.53K+118.5%
Q2 FY2017Jun 30, 2017$174.73K–
Q1 FY2017Mar 31, 2017$95.81K–
Q4 FY2016Dec 31, 2016$158.96K–
Q3 FY2016Sep 30, 2016$137.54K–

More ENDRA Life Sciences figures

See a number that looks wrong?